Genomic Instability andTP53Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment
Author(s) -
Eugene F. Schuster,
Pascal Gellert,
Corrinne V. Segal,
Elena LópezKnowles,
Richard Buus,
Maggie C.U. Cheang,
James P. Morden,
J.F.R. Robertson,
Judith M. Bliss,
Ian Smith,
Mitch Dowsett
Publication year - 2019
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00286
Subject(s) - loss of heterozygosity , genome instability , breast cancer , genotype , somatic cell , cancer , medicine , biology , oncology , cancer research , genetics , gene , allele , dna , dna damage
Although aromatase inhibitor (AI) treatment is effective in estrogen receptor-positive postmenopausal breast cancer, resistance is common and incompletely explained. Genomic instability, as measured by somatic copy number alterations (SCNAs), is important in breast cancer development and prognosis. SCNAs to specific genes may drive intrinsic resistance, or high genomic instability may drive tumor heterogeneity, which allows differential response across tumors and surviving cells to evolve resistance to treatment rapidly. We therefore evaluated the relationship between SCNAs and intrinsic resistance to treatment as measured by a poor antiproliferative response.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom